FDA Lets Pfizer Test Experimental COVID-19 Vaccine on U.S. Children – Centre for Research on Globalization

On Oct. 16, Pfizer’s CEO indicated the company would likely file for FDA Emergency Use Authorization for its experimental BNT162b2 vaccine in late November. That statement came three days after Pfizer announced that it had received FDA permission to administer the unproven vaccine to children as young as 12, becoming the first company in the U.S. to include young participants in Phase 3 trials. In the UK, Oxford and AstraZeneca gained approval to test their vaccine in children aged 5-12 back in May, a couple of months before two of their adult clinical trial participants developed transverse myelitis.

Are these parents (perhaps left unemployed by coronavirus restrictions) tempted by the financial incentives offered to clinical trial participants, reportedly anywhere from $1200 to $2000? Otherwise, their motivation for wanting to throw their children into the experimental fray is unclear; as the director of the Cincinnati Children’s Hospital stated, “most of the time, what a coronavirus causes is a cold” that does not even make children “sick enough to where a parent says they need to go to a doctor.”

The Cincinnati physician has, nonetheless, just started giving Pfizer’s shot to 16- and 17-year-olds (and soon to 12-15-year-olds). To entice additional young participants, he tells parents that the COVID-19 death rate in children is “not zero” — but declines to spell out that, according to the Centers for Disease Control and Prevention, the survival rate in those age 19 and under is 99.997%

FDA Lets Pfizer Test Experimental COVID-19 Vaccine on U.S. Children – Global ResearchGlobal Research – Centre for Research on Globalization